Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
10.53
+0.01 (0.10%)
At close: Aug 5, 2026, 4:00 PM EDT
10.39
-0.14 (-1.33%)
After-hours: Aug 5, 2026, 7:50 PM EDT
Zevra Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 145.32 | 62.41 | 33.79 | 43.05 | 65.47 | 112.35 |
Short-Term Investments | 76.25 | 128.61 | 35.71 | 24.69 | 17.38 | - |
Cash & Short-Term Investments | 221.57 | 191.01 | 69.5 | 67.74 | 82.85 | 112.35 |
Cash Growth | 9.36% | 174.85% | 2.60% | -18.24% | -26.26% | 2566.65% |
Accounts Receivable | 22.49 | 23.26 | 10.51 | 17.38 | 8.3 | 1.53 |
Inventory | 2.45 | 1.74 | 1.97 | - | - | - |
Other Current Assets | 4.79 | 7 | 4.05 | 1.82 | 1.69 | 1.18 |
Total Current Assets | 251.3 | 223.01 | 86.03 | 86.94 | 92.83 | 115.06 |
Net Property, Plant & Equipment | 2.31 | 1.7 | 1.01 | 1.53 | 1.78 | 2.03 |
Other Intangible Assets | 5.79 | 6.42 | 68.99 | 69.23 | - | - |
Goodwill | 4.7 | 4.7 | 4.7 | 4.7 | - | - |
Long-Term Investments | 38.61 | 47.88 | 6.01 | - | 20 | 15.42 |
Other Long-Term Assets | 0 | 1.02 | 11.38 | 9.94 | 0.72 | 0.44 |
Total Assets | 302.71 | 284.73 | 178.13 | 172.33 | 115.34 | 132.94 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 13.96 | 11.6 | 25.46 | 28.4 | 6.17 | 3.04 |
Accrued Expenses | 20.84 | 13.71 | - | - | - | - |
Short-Term Debt | - | - | - | 37.7 | - | - |
Current Portion of Leases | 0.63 | 0.42 | 0.42 | 0.54 | 0.48 | 0.36 |
Other Current Liabilities | 13.2 | 13.55 | 8.19 | 7.07 | 5.37 | 0.84 |
Total Current Liabilities | 48.63 | 39.28 | 34.07 | 73.72 | 12.02 | 4.23 |
Long-Term Debt | - | 61.93 | 59.5 | 5.07 | 12.8 | - |
Long-Term Leases | 0.87 | 0.86 | 0.37 | 0.46 | 0.84 | 1.23 |
Other Long-Term Liabilities | 35.56 | 28.01 | 44.52 | 31.22 | 14.55 | 0.36 |
Total Long-Term Liabilities | 36.43 | 90.8 | 104.4 | 36.74 | 28.2 | 1.59 |
Total Liabilities | 85.06 | 130.07 | 138.46 | 110.46 | 40.22 | 5.82 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
Treasury Stock | -10.98 | -10.98 | -10.98 | -10.98 | -7.54 | -2.81 |
Additional Paid-in Capital | 606.26 | 588.46 | 555.3 | 472.66 | 436.27 | 396.96 |
Accumulated Other Comprehensive Income | -2.22 | -0.76 | 0.63 | - | - | - |
Retained Earnings | -375.42 | -422.06 | -505.29 | -399.78 | -353.73 | -267.03 |
Shareholders' Equity | 217.65 | 154.66 | 39.67 | 61.91 | 75.01 | 127.12 |
Total Liabilities & Equity | 302.71 | 284.73 | 178.13 | 172.33 | 115.34 | 132.94 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.5 | 63.21 | 60.3 | 43.77 | 14.12 | 1.59 |
Net Cash (Debt) | 220.07 | 127.81 | 9.2 | 23.97 | 68.72 | 110.76 |
Net Cash Growth | 56.82% | 1289.18% | -61.62% | -65.12% | -37.95% | - |
Net Cash Per Share | 3.73 | 2.23 | 0.20 | 0.68 | 1.99 | 3.72 |
Book Value | 217.65 | 154.66 | 39.67 | 61.91 | 75.01 | 127.12 |
Book Value Per Share | 3.69 | 2.70 | 0.86 | 1.75 | 2.17 | 4.27 |
Tangible Book Value | 207.16 | 143.54 | -34.03 | -12.02 | 75.01 | 127.12 |
Tangible Book Value Per Share | 3.51 | 2.51 | -0.74 | -0.34 | 2.17 | 4.27 |